Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 2/2011

01-04-2011 | Research Article

Sequential FDG-PET/CT after Neoadjuvant Chemotherapy is a Predictor of Histopathologic Response in Patients with Head and Neck Squamous Cell Carcinoma

Authors: Masahiro Kikuchi, Shogo Shinohara, Yuji Nakamoto, Yu Usami, Keizo Fujiwara, Tsunemichi Adachi, Shin-ya Hori, Yosuke Tona, Hiroshi Yamazaki, Yukihiro Imai, Yasushi Naito

Published in: Molecular Imaging and Biology | Issue 2/2011

Login to get access

Abstract

Purpose

To evaluate whether 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) more accurately predicts the histopathologic response to neoadjuvant chemotherapy (NAC) than magnetic resonance imaging (MRI) in patients with head and neck squamous cell carcinoma (HNSCC).

Procedures

Sixteen patients with HNSCC underwent FDG-PET/CT and MRI scans before and after one cycle of NAC, followed by surgical resection. The 26 surgically resected specimens of the 16 patients were analyzed. Decreases in maximum standardized uptake value (SUVmax) or in tumor maximum size (diametermax) were calculated, and their accuracies for the prediction of histopathologic response were evaluated.

Results

In histopathologic responders (n = 7), percent decreases in SUVmax were significantly higher (P < 0.001) than in non-responders (n = 19). Applying a cut-off point of 55.5%, the histopathologic response could be predicted with a sensitivity and specificity of 86% and 95%, respectively.

Conclusion

FDG-PET/CT can predict histopathologic NAC responses with higher accuracy than MRI in HNSCC patients.
Literature
1.
Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949–955PubMed
2.
Pignon JP, le Maître A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol 92:4–14PubMedCrossRef
3.
The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1324:1685–1690
4.
Lefebvre JL, Chevalier D, Luboinski B et al (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899PubMedCrossRef
5.
Ensley JF, Jacobs JR, Weaver A et al (1984) Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54:811–814PubMedCrossRef
6.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
7.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
8.
Veit-Haibach P, Luczak C, Wanke I et al (2007) TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging 34:1953–1962PubMedCrossRef
9.
Nishiyama Y, Yamamoto Y, Yokoe K et al (2005) FDG PET as a procedure for detecting simultaneous tumours in head and neck cancer patients. Nucl Med Commun 26:239–244PubMedCrossRef
10.
Wartski M, Le Stanc E, Gontier E et al (2007) In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET-CT. Nucl Med Commun 28:365–371PubMedCrossRef
11.
Dalsaso TA, Lowe VJ, Dunphy FR et al (2007) FDG-PET and CT in evaluation of chemotherapy in advanced head and neck cancer. Clin Positron Imaging 3:1–5CrossRef
12.
Andrade RS, Heron DE, Degirmenci B et al (2006) Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 65:1315–1322PubMedCrossRef
13.
Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065PubMed
14.
Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 15:4604–4610CrossRef
15.
Benz MR, Czernin J, Allen-Auerbach MS et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856–2863PubMedCrossRef
16.
Kodaira T, Fuwa N, Tachibana H et al (2006) Phase study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 26:2265–2268PubMed
17.
Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530PubMedCrossRef
18.
Metz CE (1989) Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol 24:234–245PubMedCrossRef
19.
Cognetti F, Pinnarò P, Carlini P et al (1988) Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer. Cancer 62:251–261PubMedCrossRef
20.
Cognetti F, Pinnarö P, Ruggeri EM et al (1989) Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol 7:829–837PubMed
21.
Al-Kourainy K, Kish J, Ensley J et al (1987) Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59:233–238PubMedCrossRef
22.
Jacobs C, Goffinet DR, Goffinet L et al (1987) Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 60:1178–1183PubMedCrossRef
23.
Brun E, Kjellén E, Tennvall J et al (2002) FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24:127–135PubMedCrossRef
24.
Clark JR, Fallon BG, Dreyfuss AI et al (1988) Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer. Semin Oncol 15:35–44PubMed
25.
Yamane T, Daimaru O, Ito S et al (2004) Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J Nucl Med 45:1838–1842PubMed
26.
Bjurberg M, Henriksson E, Brun E et al (2009) Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm 24:327–332PubMedCrossRef
27.
Weber WA, Wieder H (2006) Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 33:27–37PubMedCrossRef
28.
Srinivas SM, Dhurairaj T, Basu S et al (2009) A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med 23:341–348PubMedCrossRef
29.
Hawkins DS, Schuetze SM, Butrynski JE et al (2005) [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828–8834PubMedCrossRef
Metadata
Title
Sequential FDG-PET/CT after Neoadjuvant Chemotherapy is a Predictor of Histopathologic Response in Patients with Head and Neck Squamous Cell Carcinoma
Authors
Masahiro Kikuchi
Shogo Shinohara
Yuji Nakamoto
Yu Usami
Keizo Fujiwara
Tsunemichi Adachi
Shin-ya Hori
Yosuke Tona
Hiroshi Yamazaki
Yukihiro Imai
Yasushi Naito
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 2/2011
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-010-0364-3

Other articles of this Issue 2/2011

Molecular Imaging and Biology 2/2011 Go to the issue

Research Article

A Novel In Vitro Assay to Assess Phosphorylation of 3′-[18F]fluoro-3′-Deoxythymidine

Brief Article

Motion-Artifact-Free In Vivo Imaging Utilizing Narcotized Avian Embryos In Ovo

Brief Article

Radiosynthesis and Assessment of Ocular Pharmacokinetics of 124I-Labeled Chitosan in Rabbits Using Small-Animal PET

Research Article

The Effects of Aging on Testicular Volume and Glucose Metabolism: an Investigation with Ultrasonography and FDG-PET

Research Article

In Vivo Magnetic Resonance Imaging of Injected Endothelial Progenitor Cells after Myocardial Infarction in Rats

Research Article

In Vitro and Initial In Vivo Evaluation of 68Ga-Labeled Transferrin Receptor (TfR) Binding Peptides as Potential Carriers for Enhanced Drug Transport into TfR Expressing Cells